Oxycodegol

Oxycodegol
Names
	IUPAC name (4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol
	Other names Loxicodegol; NKTR-181
Identifiers
CAS Number	1211231-76-3 ;
3D model (JSmol)	Interactive image;
DrugBank	DB14146;
IUPHAR/BPS	10652;
KEGG	D11424;
PubChem CID	73673720;
UNII	J2WIV0JMML;
	InChI InChI=1S/C31H49NO10/c1-32-9-8-30-27-23-4-5-24(35-3)28(27)42-29(30)25(6-7-31(30,33)26(32)22-23)41-21-20-40-19-18-39-17-16-38-15-14-37-13-12-36-11-10-34-2/h4-5,25-26,29,33H,6-22H2,1-3H3/t25-,26+,29-,30-,31+/m0/s1 Key: RQHILGKAOIGUHU-XPLSERNMSA-N;
	SMILES CN1CC[C@]23[C@@H]4[C@H](CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O)OCCOCCOCCOCCOCCOCCOC;
Properties
Chemical formula	C31H49NO10
Molar mass	595.730 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Oxycodegol (also known as loxicodegol and NKTR-181) is an experimental μ-opioid receptor agonist for the treatment of pain.^[1]^[2] It has had success for back pain as an alternative to traditional opioids,^[3] which have potential for abuse. It acts more slowly on the central nervous system, reducing risk for abuse and respiratory depression.^[1]

^ ^a ^b Advokat, Claire D.; Comaty, Joseph E.; Julien, Robert M. (2019). Julien's Primer of Drug Action: a comprehensive guide to the actions, uses, and side effects of psychoactive drugs. New York: Worth Publishers. p. 565. ISBN 978-1-319-20054-1.
^ "NKTR-181 (Oxycodegol) Oral Tablets for. Chronic Low Back Pain". Food and Drug Administration. Archived from the original on 24 December 2020.
^ Markman, John; Gudin, Jeffrey; Rauck, Richard; Argoff, Charles; Rowbotham, Matthew; Agaiby, Eva; Gimbel, Joseph; Katz, Nathaniel; Doberstein, Stephen K; Tagliaferri, Mary; Lu, Lin; Saddhanti, Suresh; Hale, Martin (June 2019). "SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain". PAIN. 160 (6): 1374–1382. doi:10.1097/j.pain.0000000000001517. PMC 6553961. PMID 30747908.

[ACJ-1] Advokat, Claire D.; Comaty, Joseph E.; Julien, Robert M. (2019). Julien's Primer of Drug Action: a comprehensive guide to the actions, uses, and side effects of psychoactive drugs. New York: Worth Publishers. p. 565. ISBN 978-1-319-20054-1.

[2] "NKTR-181 (Oxycodegol) Oral Tablets for. Chronic Low Back Pain". Food and Drug Administration. Archived from the original on 24 December 2020.

[3] Markman, John; Gudin, Jeffrey; Rauck, Richard; Argoff, Charles; Rowbotham, Matthew; Agaiby, Eva; Gimbel, Joseph; Katz, Nathaniel; Doberstein, Stephen K; Tagliaferri, Mary; Lu, Lin; Saddhanti, Suresh; Hale, Martin (June 2019). "SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain". PAIN. 160 (6): 1374–1382. doi:10.1097/j.pain.0000000000001517. PMC 6553961. PMID 30747908.

[1]

[2]

[3]